Andere talen Arrowhead Pharmaceuticals, Inc.

Aandelen

ARWR

US04280A1007

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
22,12 ^USD	+1,14%		-0,94%	-27,71%

24/04	Arrowhead Pharmaceuticals start Fase 1/2a studie van ARO-CFB voor de behandeling van complement-gemedieerde nierziekte	CI
07/04	Arrowhead Pharmaceuticals, Inc. Kondigt nieuwe Fase 2-gegevens van plozasiran aan, gepubliceerd in JAMA Cardiology en gepresenteerd op de 73e jaarlijkse wetenschappelijke sessie en tentoonstelling van het American College of Cardiology	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars	13:31
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results	24/04
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	24/04
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	24/04
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	07/04
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	07/04
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	01/04
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data	25/03
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	25/03
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise	08/03
Arrowhead Pharmaceuticals : 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference View Presentation	08/03
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	08/03
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	08/03
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences	04/03
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	03/03
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	03/03
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024	22/02
Sector Update: Health Care Stocks Firmer Late Afternoon	07/02
Sector Update: Health Care Stocks Advance in Afternoon Trading	07/02
Sector Update: Health Care Stocks Mixed Premarket Wednesday	07/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arrowhead Pharmaceuticals, Inc.

Aandelen

ARWR

US04280A1007

Andere talen

Filters